Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
fenofibrate · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Fenofibrate U.S. Formulation |
| 2 | ACTIVE_COMPARATOR | Fenofibrate UK Formulation |
| Name | Type | Description |
|---|---|---|
| fenofibrate (U.S. formulation) | DRUG | Single dose of 160 mg fenofibrate U.S. formulation (Tricor®) in one of two treatment periods. |
| fenofibrate (UK formulation) | DRUG | Single dose of 160 mg fenofibrate UK formulation (Supralip®) in one of two treatment periods. |
Inclusion Criteria: * Subject is in good health * Subject is willing to follow all study guidelines Exclusion Criteria: * Subject has uncontrolled high blood pressure, impaired glucose tolerance, diabetes, or other major diseases or chronic conditions that would confound the results of the study ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 2 | PHASE3 | Lepodisiran |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Enlicitide, Rosuvastatin |
| NewAmsterdam Pharma Company N.V. | NAMS | 3 | PHASE3 | obicetrapib, ezetimibe daily |
| AstraZeneca PLC | AZN | 3 | PHASE2 | AZD0780, Rosuvastatin |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE1 | ARO-DIMERPA |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX310 |
| HeartFlow, Inc. | HTFL | 1 | N/A | Rosuvastatin |
Fenofibrate is a small molecule used for dyslipidemia, a condition characterized by abnormal levels of lipids in the blood. It is being developed by Merck & Company, Inc. (MRK) as a potential treatment for this cardiovascular condition.
Fenofibrate is being developed by Merck & Company, Inc., which is publicly traded under the ticker symbol MRK. The company is conducting clinical research on this small molecule for the treatment of dyslipidemia.
Fenofibrate is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains in early-stage clinical development.
Fenofibrate has one completed Phase 1 clinical trial, identified as NCT00928694, titled "Fenofibrate Bioequivalence Study (0767-031)". This trial enrolled 14 participants with dyslipidemia and was active-controlled, though it was not double-blinded.
Fenofibrate is a distinct drug entity. It is not known to be the same as any other drug under a different name. It is being studied specifically for its effects on dyslipidemia in a Phase 1 clinical trial.